MILESTONES IN THE ERA OF EFFECTIVE HIV TREATMENTThe fi rst HIV med, Retrovir (zidovudine, or AZT), was approved in 1987. Over the next few years, additional antiretrovirals (ARVs) were introduced in the same drug class (nucleoside reverse transcriptase inhibitors, also known as NRTIs, or nukes). But using only one or two meds from the same drug class wasn’t enough to fully suppress the virus, and the crisis period of the epidemic raged on. In December 1995, the fi rst protease inhibitor (PI), Invirase (saquinavir), was approved, and a new era of combination therapy was set to begin. Here’s a timeline of the highlights:

At the 11th International AIDS Conference in Vancouver, numerous studies demonstrate the effi cacy of triple-combination antiretroviral (ARV) treatment, ushering in the era of what was then called highly active antiretroviral treatment, or HAART.

The fi rst viral load test is approved.

The fi rst non-nucleoside

reverse transcriptase

inhibitor (NNRTI, or non-nuke),

Viramune (nevirapine), is

approved.

199

6

199

7

199

8

20

01

20

02

20

03

20

06

20

07

20

08

20

10

20

11

20

12

20

13

20

14

20

15

The fi rst combination ARV tablet, Combivir (zidovudine/lamivudine), is approved.

AIDS-related deaths drop 47 percent in one year.

The Global Fund to Fight AIDS, Tuberculosis and Malaria in developing nations is launched.

President George W. Bush

launches the U.S. President’s

Emergency Plan for AIDS Relief,

or PEPFAR, pledging to

spend $15 billion to combat the

disease in poorer nations in fi ve years.

The fi rst once-daily, single-tablet ARV

regimen, Atripla (efavirenz/TDF/

emtricitabine), is approved.

The SMART trial is stopped early. The expansive global study investigated whether interrupting HIV treatment

could reduce the risk of diseases thought to be the

result of ARV toxicities. But those who interrupted

treatment actually had worse health outcomes.

The surprise fi ndings spur research into the

link between HIV, chronic infl ammation and non-AIDS-

defi ning conditions such as heart

disease.

The fi rst integrase inhibitor, Isentress (raltegravir), is approved.

The fi rst oral entry inhibitor, Selzentry (maraviroc), is approved.

As HIV treatments improve, U.S. treatment guidelines up the CD4 threshold for starting ARVs to 350.

As San Francisco recommends HIV treatment regardless of CD4 count, U.S. guidelines advise starting ARVs when CD4s drop to 500, while the threshold set by the World Health Organization (WHO) is 350 CD4s.

The HPTN 052 study fi nds that starting

ARVs reduces the risk of transmitting HIV

through heterosexual sex by 96 percent,

launching the treat-ment-as-prevention

(TasP) era.

U.S. guidelines recommend treatment for all people living with HIV, regardless of their CD4 count.

The FDA approves

Truvada (TDF/emtricitabine)

for use as pre-exposure

prophylaxis(PrEP).

UNAIDS reports that global AIDS-related deaths have fallen 30 percent since peaking in 2005.

WHO recommends

treatment once CD4s hit 500 or below.

Interim results from the ongoing

PARTNER study fi nd that there have been

no transmissions between partners

in gay or straight mixed-HIV-status

couples in which the HIV-positive

partner has an undetectable

viral load. Researchers

estimate that the actual

transmission risk may

be close to zero, or in fact zero.

The placebo arm of the global START trial is terminated early when it becomes clear that there is a lower risk of various negative health outcomes associated with starting ARVs when CD4s are above 500 compared with waiting until they hit 350. In response, WHO supports treatment for all, regardless of CD4 count.

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, or TAF) is the fi rst approved combination tablet to include an updated version of tenofovir that is safer for bones and kidneys.

ment-as-prevention (TasP) era.

The FDapprove

Truvuvadada (TDemtrtrici itabin

fofor use apre-exexposu

propophyhylax(P(PrEP

Gen(elvcobemttenoalafor T

The U.S. Department of Health and Human Services issues the fi rst federal HIV treatment guidelines, recommending treatment for those with fewer than 500 CD4s, in keeping with the “hit early, hit hard” philosophy of the time.

Viread (tenofovir disoproxil

fumarate, or TDF), which comes

with bone and kidney toxicities, is approved and

goes on to become the most widely prescribed ARV.

ALL IMAGES: ISTOCK (MODELS USED FOR ILLUSTRATIVE PURPOSES ONLY)

In an about-face, U.S. treatment

guidelines switch to recommending

starting ARVs when CD4s have dropped

to 200 or below.

1999999

66

the pa

u

e

t

199

9

200

0

20

04

20

05

20

09

The fi rst entry inhibitor, the injectable Fuzeon (enfuvirtide), is approved.

Norvir (ritonavir),

a PI that would become

a booster of other ARVs, is

approved.

P07-16_Insert_Timeline_HY.indd 1 6/2/16 12:36 PM

cocobememte

or T

9996

pa

ee

ment-as-prevention

The fi rst entry

era.

GenGen

alafthe

Trem

20

13

prpre-

ap

(ritonavir),

te

pr

fo

u

200

0

(T

200

020

00

20

09

(elv

t

9

200

0

20

05

199

9

20

149

20

06

20

13

20

14

20

02

20

06

20

02

20

10

20

07

20

09

200

0

POZ14477-00_GatefoldInsert.pgs 06.02.2016 12:39

ANSWERSYOU DESERVE

HIV Answers gives you the information you want, privately, right on your phone.

Get started online at

HIVanswers.comDownload the app at

HIVanswers.com/appAnswers

UNBC3324 05/16

UNBC3324_Fenuxe_HIV_Answers_7.375x10.5.indd 1 5/13/16 3:27 PM

HOW DO WE HELP STOP HIV?A. PREVENT IT.B. TEST FOR IT. C. TREAT IT.D. ALL OF THE ABOVE.

© 2016 Gilead Sciences, Inc. All rights reserved. UNBC3323 05/16

Learn how it all works together at HelpStopTheVirus.com

UNBC3323_7.625x10.5.indd 1 5/16/16 11:09 AM

TREATMENT LOWERS THE AMOUNT OF HIV IN YOUR BODY.AND HELPS LOWER THE CHANCE OF PASSING HIV ON.

© 2016 Gilead Sciences, Inc. All rights reserved. UNBC3321 05/16

There is no cure for HIV, but treatment can help protect your health and the people you care about. Talk to a healthcare provider and visit HelpStopTheVirus.com

UNBC3321_STV_PrintAds_7.875x10.5.indd 1

P07-16_Gatefold_HY.indd 1 6/8/16 11:17 AM